TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21173095
Drug: Subcutaneous veltuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous veltuzumab 320 mg
Study: 21173095
Drug: Subcutaneous veltuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous veltuzumab (all doses combined)
Study: 21173101
Drug: FBS0701, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBS0701, a novel oral iron chelator, given daily for 7 days at doses up to 32 mg/kg
Study: 21173101
Drug: FBS0701, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBS0701, a novel oral iron chelator
Study: 21174506
Drug: Standard-of-care with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care with atorvastatin 80 mg
Study: 21176218
Drug: 15-20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-20 ml/kg of 4°C cold normal saline (TH group)
Study: 21176218
Drug: TH group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH group with 17 ml/kg of cold saline
Study: 21176752
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg administered after HD during a 48 h - 48 h - 72 h dialysis week.
Study: 21176752
Drug: Daptomycin 6
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 6 mg/kg administered before a CAPD dwell time over a 48 h - 48 h - 48 h dialysis week.
Study: 21177912
Drug: 4CMenB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB (3 doses at baseline, 2 months, and 6 months)
Study: 21177912
Drug: MenACWY-CRM (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY-CRM (1 dose 1 month after 4CMenB)
Study: 21178394
Drug: Novel synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel synthetic TB subunit vaccine
Study: 21178655
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg famciclovir
Study: 21180274
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment after 101-200 days (n = 6)
Study: 21188121
Drug: Resveratrol/GP (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol/GP (80 g of grape powder per day)
Study: 21191530
Drug: Injectable risperidone
Normalized name: risperidone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable risperidone long-acting therapy (25-50mg, injected every 2 weeks)
Study: 21191530
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole (5-30mg/day)
Study: 21194015
Drug: Clock Drawing
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clock Drawing Test (CDT) administered at all time points
Study: 21194419
Drug: Potassium control-target
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium control-target of 4.0 mmol/L
Study: 21194419
Drug: Potassium control-target
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium control-target of 4.5 mmol/L
Study: 21200021
Drug: Interferon α
Normalized name: Interferon α-2b
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon α (IFNα) treatment
Study: 21203574
Drug: Preparations for
Normalized name: ANTI-ACNE PREPARATIONS FOR TOPICAL USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparations for delivery
Study: 21205021
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation in type 1 diabetic patients
Study: 21206909
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg p.o. twice daily continuously
Study: 21208151
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl orally disintegrating tablet (ODT)
Study: 21209881
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo pioglitazone treatment
Study: 21211990
Drug: Rituximab (anti-CD20)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (anti-CD20) therapy
Study: 21216311
Drug: MVA-HIV (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-HIV (high dose 10^9 pfu/2 ml)
Study: 21216475
Drug: Various medications
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various medications administered in level 3
Study: 21217520
Drug: Granulocyte-macrophage colony-stimulating
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy
Study: 21219411
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous sildenafil bolus
Study: 21219411
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral sildenafil tablet
Study: 21219434
Drug: Always used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Always used injection-meal interval (Type 1 diabetes); n=39, age 58 years, duration of diabetes 21.1 years, BMI 28.7 kg/m², HbA(1c) 7.50%/58 mmol/mol
Study: 21219434
Drug: Always used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Always used injection-meal interval (Type 2 diabetes); n=124, age 65 years, duration of diabetes 13.8 years, BMI 32.6 kg/m², HbA(1c) 7.31%/56 mmol/mol
Study: 21220472
Drug: CBP501 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501 alone (0.9 mg/m(2), D1/D8/D15, q4w)
Study: 21220472
Drug: CBP501 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501 in combination with cisplatin (3.6 mg/m(2) CBP501, 50 mg/m(2) cisplatin, both on D1, q3w)
Study: 21220472
Drug: CBP501/cisplatin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501/cisplatin combination
Study: 21220675
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (ChEIs) and memantine hydrochloride
Study: 21220675
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (ChEIs) only
Study: 21224368
Drug: CT-322 (BMS-844203)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CT-322 (BMS-844203) 2 mg/kg i.v. weekly (qw) or biweekly (q2w)
Study: 21224368
Drug: CT-322 (BMS-844203)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CT-322 (BMS-844203) 0.1 to 3.0 mg/kg i.v. qw or q2w
Study: 21224368
Drug: CT-322 (BMS-844203)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CT-322 (BMS-844203) 3.0 mg/kg i.v. qw or q2w
Study: 21226540
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between omega-3 index and fasting insulin level
Study: 21226927
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg loading dose, followed by 75 mg daily)
Study: 21226927
Drug: Aspirin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (500 mg loading dose, followed by 100 mg daily)
Study: 21226927
Drug: Structured therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured therapy plan based on a 'test and treat' strategy
Study: 21232745
Drug: MMP-1 G
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMP-1 G insertion
Study: 21233271
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Ataluren (PTC124) lower dose (4, 4 and 8 mg·kg(-1))
Study: 21233271
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Ataluren (PTC124) higher dose (10, 10 and 20 mg·kg(-1))
Study: 21234288
Drug: Breast health
Normalized name: Ascorbic Acid/Bioflavonoid/Broccoli/Curcumin/Flaxseed/Genistein/Selenium 100 MG-50 MG-85 MG-300 MG-200 MG-10 MG-0.1 MG Oral Tablet [PROHERBS BREAST HEALTH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast health supplement containing HMR lignan, indole-3-carbinol, calcium glucarate, milk thistle, Schisandra chinesis and stinging nettle for 28 days
Study: 21239695
Drug: Bendamustine 90
Normalized name: bendamustine 90 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 90 mg/m² days 1 and 4; Rituximab 375 mg/m² day 1; Bortezomib 1.3 mg/m² days 1, 4, 8, 11 (6 cycles of 28 days)
Study: 21239695
Drug: Bendamustine, Bortezomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine, Bortezomib, and Rituximab combination
Study: 21239698
Drug: Flavopiridol (30-mg/m(2)
Normalized name: M
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol (30-mg/m(2) bolus, 60-mg/m(2) infusion)
Study: 21239698
Drug: Flavopiridol (30-mg/m(2)
Normalized name: M
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavopiridol (30-mg/m(2) bolus, 70-mg/m(2) infusion)
Study: 21242187
Drug: Re-induction therapy
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-induction therapy
Study: 21242491
Drug: Tandutinib 500
Normalized name: Tandutinib
DrugBank: Tandutinib (DB05465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandutinib 500 mg twice daily
Study: 21242992
Drug: Sertraline (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (open-label treatment for 8 weeks)
Study: 21244307
Drug: Ropinirole prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole prolonged release (PR), maximum 24 mg/day
Study: 21245420
Drug: Adjuvant trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant trastuzumab with chemotherapy
Study: 21249218
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite infusion (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr)
Study: 21249218
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite infusion at maximal tolerated dose
Study: 21251631
Drug: Combination SYNTAX-PAMI
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination SYNTAX-PAMI score
Study: 21251673
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alfuzosin XL for 12 months
Study: 21252240
Drug: Incretin effect
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin effect measured over 6 days with three 4-h oral glucose tolerance tests (25, 75, and 125 g)
Study: 21252240
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance tests with increasing glucose loads
Study: 21252240
Drug: Incretin hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incretin hormone responses
Study: 21253319
Drug: Overall chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall chemotherapy (FOLFOX and XELOX)
Study: 21253319
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior chemotherapy
Study: 21255766
Drug: Any antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antidepressant
Study: 21255766
Drug: Guideline-level antidepressant
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-level antidepressant dose and duration
Study: 21255766
Drug: Serotonergic antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressants and individual psychotherapy
Study: 21256189
Drug: Ag85B-ESAT-6 combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ag85B-ESAT-6 combined with the adjuvant IC31(®), administered at 0 and 2 months
Study: 21262916
Drug: Carboplatin/pemetrexed therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/pemetrexed therapy
Study: 21263104
Drug: Baseline macroalbuminuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline macroalbuminuria treated with ACE inhibitor/ARB
Study: 21267044
Drug: 24-hour intravenous
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour intravenous patient-controlled analgesia (IV-PCA) with oxymorphone
Study: 21267531
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation with capecitabine (825 mg/m² twice a day on radiotherapy days; weeks 1-4) and oxaliplatin (50 mg/m² intravenously on days 1, 8, 15, and 22) with radiotherapy (total dose 45 Gy)
Study: 21267960
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitors (88%)
Study: 21267960
Drug: Beta-blockers (77%)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (77%)
Study: 21267960
Drug: Both converting
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both converting enzyme inhibitors and beta-blockers (60%)
Study: 21273144
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting balloons (DEB) including SeQuent Please, In.Pact Falcon, New Dior, Pantera Lux
Study: 21273144
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting balloons (DEB)
Study: 21273493
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro with rHuPH20
Study: 21273493
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI) with rHuPH20
Study: 21273493
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro without rHuPH20
Study: 21273493
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (RHI) without rHuPH20
Study: 21273938
Drug: Trivalent, inactivated
Normalized name: poliomyelitis, trivalent, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent, inactivated influenza vaccine (TIV), 2 doses
Study: 21274359
Drug: Multimodal lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal lifestyle intervention (11 group sessions and weekly fitness training for 5 months)
Study: 21274364
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patches (4.6 mg/24 h)
Study: 21274364
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 to 10 mg/d)
Study: 21277691
Drug: High-energy focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy focused extracorporeal shockwave therapy
Study: 21281234
Drug: GM-ELISA- and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-ELISA- and Aspergillus PCR-driven antifungal therapy
Study: 21281234
Drug: Standard fever-driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fever-driven empiric antifungal treatment strategy
Study: 21282484
Drug: Subgroup analysis
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup analysis of patients with idiopathic PAH and those with PAH associated with drugs and toxins
Study: 21284479
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring with microdialysis-based subcutaneous glucose monitoring system
Study: 21288612
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement (WPS) 60 g/day for 4 weeks
Study: 21289257
Drug: Oral water
Normalized name: Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral water load
Study: 21289257
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 3% saline
Study: 21289369
Drug: Sunitinib (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (second line treatment)
Study: 21293986
Drug: Hard drug
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard drug use (cocaine, amphetamines, or heroin)
Study: 21296274
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) as salvage treatment after prostatic radiotherapy
Study: 21296824
Drug: Reading Practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading Practice with Sequential Presentation of Lexical Information (module 3)
Study: 21299393
Drug: BD GGBP
Normalized name: BD-111
DrugBank: BD-111 (DB18247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD GGBP sensor (intradermal placement)
Study: 21299393
Drug: BD GGBP
Normalized name: BD-111
DrugBank: BD-111 (DB18247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD GGBP sensor (subcutaneous placement)
Study: 21300307
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT) using an implanted device (Rheos)
Study: 21300566
Drug: Adjuvanted HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted HIV-1 vaccine candidate
Study: 21300924
Drug: Oral vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vorinostat (200 mg twice daily on days 1-14 of a 21-day cycle)
Study: 21304070
Drug: Ultrasmall superparamagnetic
Normalized name: Ultrasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasmall superparamagnetic particles of iron oxide (USPIO) administered before and 24 to 36 hours after MRI imaging
Study: 21304982
Drug: MF59-adjuvanted pH1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted pH1N1 vaccine (Focetria®, Novartis) administered twice
Study: 21308151
Drug: Givinostat (ITF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givinostat (ITF 2357), an orally active HDAC inhibitor, administered for 12 weeks.
Study: 21308151
Drug: Control not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control not specified, but implied comparison to standard treatments like methotrexate and anticytokines.
Study: 21310866
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with pyridoxine hydrochloride (40 mg/d) for 1 month
Study: 21311383
Drug: Intravenous Magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Magnesium Sulphate
Study: 21311694
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow mononuclear cells (BMMC) infusion after granulocyte colony-stimulating factor administration.
Study: 21311694
Drug: BMMC cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMC cell therapy
Study: 21320979
Drug: anti-inflammatory treatment
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-inflammatory treatment
Study: 21321062
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (1 mg/d) for 8 weeks
Study: 21321062
Drug: Low folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low folate diet for 12 weeks followed by folic acid repletion (1 mg/d) for 4 weeks
Study: 21324375
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of AS03-adjuvanted H1N1 influenza vaccine
Study: 21324375
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of AS03-adjuvanted H1N1 influenza vaccine
Study: 21325343
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (25[OH]D < 20 ng/mL)
Study: 21325343
Drug: Increases in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increases in 25(OH)D to greater than or equal to 20 ng/mL
Study: 21328719
Drug: Haloperidol (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (first generation antipsychotic)
Study: 21328719
Drug: Olanzapine (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (second generation antipsychotic)
Study: 21329725
Drug: Tenofovir discontinuation
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir discontinuation
Study: 21334595
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab injected monthly for one year
Study: 21338641
Drug: Sorafenib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (800 mg/d) plus metronomic tegafur/uracil (250 mg/m(2)/d)
Study: 21338641
Drug: K(trans) change
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K(trans) change after treatment
Study: 21345726
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg) and Bortezomib (1.6 mg/m2)
Study: 21349999
Drug: Brivanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib (800 mg orally once daily)
Study: 21352516
Drug: Web-enabled mobile
Normalized name: Enablex
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Web-enabled mobile phone intervention with daily online entries and individualized written feedback
Study: 21352601
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg orally administered AS (artesunate)
Study: 21355002
Drug: Belotecan (CKD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belotecan (CKD 602) at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Study: 21355077
Drug: Langerhans cell
Normalized name: Allogeneic human pancreatic islets of Langerhans
DrugBank: Allogeneic human pancreatic islets of Langerhans (DB18651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Langerhans cell (LC) vaccines
Study: 21355077
Drug: monocyte-derived dendritic
Approvals — FDA: no, EMA: no, PMDA: no
Description: monocyte-derived dendritic cell (moDC) vaccines